

Giulia Renda

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4679585/giulia-renda-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

63

papers

1,763

citations

22

h-index

41

g-index

75

ext. papers

2,157

ext. citations

5

avg, IF

4.4

L-index

#	Paper	IF	Citations
63	Predictive Value of Left Atrial and Ventricular Strain for the Detection of Atrial Fibrillation in Patients With Cryptogenic Stroke.. <i>Frontiers in Cardiovascular Medicine</i> , 2022 , 9, 869076	5.4	0
62	Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease. <i>Circulation</i> , 2021 , 144, 1323-1343	16.7	9
61	Clinical outcome with different doses of low-molecular-weight heparin in patients hospitalized for COVID-19. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 52, 782-790	5.1	6
60	Clustering of blood cell count abnormalities and future risk of death. <i>European Journal of Clinical Investigation</i> , 2021 , 51, e13562	4.6	2
59	Antithrombotic therapy after percutaneous coronary intervention of bifurcation lesions. <i>EuroIntervention</i> , 2021 , 17, 59-66	3.1	6
58	Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry. <i>Internal and Emergency Medicine</i> , 2021 , 16, 591-599	3.7	3
57	Contribution of Atrial Fibrillation to In-Hospital Mortality in Patients With COVID-19. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021 , 14, e009375	6.4	9
56	Case Report: Mitral Valve Involvement and First-Degree Atrial-Ventricular Block in Two Patients With Multisystem Inflammatory Syndrome in Children. <i>Frontiers in Pediatrics</i> , 2021 , 9, 676934	3.4	0
55	Prognostic Significance of Chest Imaging by LUS and CT in COVID-19 Inpatients: The ECOVID Multicenter Study. <i>Respiration</i> , 2021 , 1-10	3.7	3
54	Updated antithrombotic strategies to reduce the burden of cardiovascular recurrences in patients with chronic coronary syndrome. <i>Biomedicine and Pharmacotherapy</i> , 2021 , 140, 111783	7.5	
53	Thromboembolic and bleeding risk in obese patients with atrial fibrillation according to different anticoagulation strategies. <i>International Journal of Cardiology</i> , 2020 , 318, 67-73	3.2	4
52	Prevention of contrast-induced nephropathy with urine alkalization: the TEATE study design. <i>Journal of Cardiovascular Medicine</i> , 2020 , 21, 65-72	1.9	1
51	Non-Vitamin K Oral Anticoagulants (NOAC) Versus Vitamin K Antagonists (VKA) for Atrial Fibrillation with Elective or Urgent Percutaneous Coronary Intervention: A Meta-Analysis with a Particular Focus on Combination Type. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	14
50	Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and atrial thrombosis: An appraisal of current evidence. <i>Archives of Cardiovascular Diseases</i> , 2020 , 113, 642-651	2.7	3
49	Mortality Prediction of the CHADS-VASc Score, the HAS-BLED Score, and Their Combination in Anticoagulated Patients with Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	8
48	Platelet Indices and Risk of Death and Cardiovascular Events: Results from a Large Population-Based Cohort Study. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 1773-1784	7	11
47	Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation. <i>American Journal of Medicine</i> , 2019 , 132, 749-757.e5	2.4	34

46	The co-predictive value of a cardiovascular score for CV outcomes in diabetic patients with no atrial fibrillation. <i>Diabetes/Metabolism Research and Reviews</i> , 2019 , 35, e3145	7.5	4
45	CHADSVASc score and adverse outcomes in middle-aged individuals without atrial fibrillation. <i>European Journal of Preventive Cardiology</i> , 2019 , 26, 1987-1997	3.9	12
44	Thrombotic and hemorrhagic burden in women: Gender-related issues in the response to antithrombotic therapies. <i>International Journal of Cardiology</i> , 2019 , 286, 198-207	3.2	13
43	Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. <i>Nature Reviews Cardiology</i> , 2019 , 16, 113-130	14.8	37
42	Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF - HF substudy. <i>International Journal of Cardiology</i> , 2018 , 265, 141-147	3.2	26
41	Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy. <i>Archives of Cardiovascular Diseases</i> , 2018 , 111, 74-84	2.7	14
40	Prognostic significance of noncardiac syncope in the general population: A systematic review and meta-analysis. <i>Journal of Cardiovascular Electrophysiology</i> , 2018 , 29, 1641-1647	2.7	8
39	Direct Oral Anticoagulants Halve Thromboembolic Events After Cardioversion of AF Compared With Warfarin. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 1984-1986	15.1	9
38	Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy - A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATION registries. <i>International Journal of Cardiology</i> , 2018 , 270, 160-166	3.2	15
37	Insulin-Requiring Versus Noninsulin-Requiring Diabetes and Thromboembolic Risk in Patients With Atrial Fibrillation: PREFER in AF. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 409-419	15.1	46
36	Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. <i>Circulation</i> , 2017 , 135, 1273-1275	16.7	94
35	Intracardiac thrombi during warfarin anticoagulation - A case report and a brief literature review. <i>Cor Et Vasa</i> , 2017 , 59, e277-e281	0.3	2
34	Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE-AF-TIMI 48 Trial. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 1372-1382	15.1	87
33	Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 1363-1371	15.1	84
32	Non-Vitamin K Antagonist Oral Anticoagulants for Cardioversion in Atrial Fibrillation: An Updated Meta-analysis. <i>American Journal of Medicine</i> , 2017 , 130, 457-461	2.4	16
31	The left atrial appendage: from embryology to prevention of thromboembolism. <i>European Heart Journal</i> , 2017 , 38, 877-887	9.5	41
30	Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation. <i>American Journal of Medicine</i> , 2016 , 129, 1117-1123.e2	2.4	12
29	History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. <i>American Heart Journal</i> , 2016 , 175, 175-83	4.9	10

28	Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials. <i>American Journal of Medicine</i> , 2015 , 128, 1007-14.e2	2.4	29
27	Genetic determinants of cognitive responses to caffeine drinking identified from a double-blind, randomized, controlled trial. <i>European Neuropsychopharmacology</i> , 2015 , 25, 798-807	1.2	20
26	Coffee and Hypertension 2015 , 395-402		
25	Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A state-of-the-art paper. <i>European Heart Journal</i> , 2014 , 35, 2213-23b	9.5	55
24	Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe. <i>Heart</i> , 2014 , 100, 1625-35	5.1	20
23	The new oral anticoagulants in atrial fibrillation: once daily or twice daily?. <i>Vascular Pharmacology</i> , 2013 , 59, 53-62	5.9	20
22	Increased short-term blood pressure variability is associated with early left ventricular systolic dysfunction in newly diagnosed untreated hypertensive patients. <i>Journal of Hypertension</i> , 2013 , 31, 1653-81	1.9	30
21	Impact of antiplatelet therapy in heart disease. <i>Advances in Cardiology</i> , 2012 , 47, 5-19		4
20	Genetic determinants of blood pressure responses to caffeine drinking. <i>American Journal of Clinical Nutrition</i> , 2012 , 95, 241-8	7	46
19	Clinical use of aspirin in ischemic heart disease: past, present and future. <i>Current Pharmaceutical Design</i> , 2012 , 18, 5215-23	3.3	7
18	Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences. <i>Arthritis and Rheumatism</i> , 2011 , 63, 850-9		47
17	Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. nonselective COX-2 inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2010 , 69, 303-6	3.8	5
16	Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. <i>European Heart Journal</i> , 2010 , 31, 2133-40	9.5	26
15	Inconsistency of different methods for assessing ex vivo platelet function: relevance for the detection of aspirin resistance. <i>Haematologica</i> , 2010 , 95, 2095-101	6.6	14
14	New anticoagulants for atrial fibrillation. <i>Journal of Cardiovascular Medicine</i> , 2009 , 10, 446-53	1.9	3
13	Facilitated PCI: rationale, current evidence, open questions, and future directions. <i>Journal of Cardiovascular Pharmacology</i> , 2008 , 51, 3-10	3.1	11
12	Awake blood pressure variability, inflammatory markers and target organ damage in newly diagnosed hypertension. <i>Hypertension Research</i> , 2008 , 31, 2137-46	4.7	63
11	Surgical bleeding after pre-operative unfractionated heparin and low molecular weight heparin for coronary bypass surgery. <i>Haematologica</i> , 2007 , 92, 366-73	6.6	17

10	Awake systolic blood pressure variability correlates with target-organ damage in hypertensive subjects. <i>Hypertension</i> , 2007 , 50, 325-32	8.5	216
9	Rapid decline of collateral circulation increases susceptibility to myocardial ischemia: the trade-off of successful percutaneous recanalization of chronic total occlusions. <i>Journal of the American College of Cardiology</i> , 2006 , 48, 59-65	15.1	51
8	Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 80, 115-25	6.1	25
7	Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 80, 264-74	6.1	89
6	Optimal duration of antiplatelet therapy in recipients of coronary drug-eluting stents. <i>Drugs</i> , 2005 , 65, 725-32	12.1	28
5	Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. <i>Journal of the American College of Cardiology</i> , 2005 , 45, 1295-301	15.1	225
4	Late coronary thrombosis after drug-eluting stent: stent vs patient-driven prescription of aspirin-clopidogrel combination. <i>Thrombosis and Haemostasis</i> , 2004 , 92, 668-669	7	7
3	Late coronary thrombosis after drug-eluting stent: stent vs patient-driven prescription of aspirin-clopidogrel combination. <i>Thrombosis and Haemostasis</i> , 2004 , 92, 668-9	7	2
2	Effects of nimesulide on constitutive and inducible prostanoid biosynthesis in human beings. <i>Clinical Pharmacology and Therapeutics</i> , 1998 , 63, 672-81	6.1	40
1	Atrial Fibrillation: Current and Forthcoming Antithrombotic Therapies 285-305		